智通财经网·2025-06-12 11:41Core Viewpoint - BioNTech has agreed to acquire CureVac for approximately $1.25 billion in an all-stock deal, enhancing its oncology business and ending a long-standing competitive relationship [1][2]. Group 1: Acquisition Details - The acquisition price offers CureVac shareholders about 5.46 shares of BioNTech for each CureVac share, representing a 34% premium over CureVac's closing price prior to the announcement [1]. - Following the transaction, CureVac shareholders will hold between 4% to 6% of BioNTech's shares [1]. - CureVac's stock rose by 31.20% in pre-market trading after the announcement [1]. Group 2: Strategic Shift - CureVac has shifted its focus from infectious disease research to cancer immunotherapy, having sold its vaccine business to GlaxoSmithKline [2]. - BioNTech's CEO, Ugur Sahin, emphasized that oncology is a key area for BioNTech, and the acquisition will integrate complementary resources to enhance its cancer treatment capabilities [2]. Group 3: Government Involvement - The German government, which holds a 13.3% stake in CureVac, will receive approximately $163 million in BioNTech stock as part of the deal [2]. - The German government has expressed a positive attitude towards the transaction [2]. Group 4: Broader Business Strategy - This acquisition is part of BioNTech's strategy to reinvest substantial funds from its COVID-19 vaccine success into expanding its cancer treatment business [2]. - Earlier this month, BioNTech licensed a new generation cancer drug to Bristol-Myers Squibb for up to $11.1 billion [2].